112 related articles for article (PubMed ID: 37778291)
21. Dual inhibition of MEK1/2 and MEK5 suppresses the EMT/migration axis in triple-negative breast cancer through FRA-1 regulation.
Hoang VT; Matossian MD; La J; Hoang K; Ucar DA; Elliott S; Burks HE; Wright TD; Patel S; Bhatt A; Phamduy T; Chrisey D; Buechlein A; Rusch DB; Nephew KP; Anbalagan M; Rowan B; Cavanaugh JE; Flaherty PT; Miele L; Collins-Burow BM; Burow ME
J Cell Biochem; 2021 Aug; 122(8):835-850. PubMed ID: 33876843
[TBL] [Abstract][Full Text] [Related]
22. Silencing β3 Integrin by Targeted ECO/siRNA Nanoparticles Inhibits EMT and Metastasis of Triple-Negative Breast Cancer.
Parvani JG; Gujrati MD; Mack MA; Schiemann WP; Lu ZR
Cancer Res; 2015 Jun; 75(11):2316-2325. PubMed ID: 25858145
[TBL] [Abstract][Full Text] [Related]
23. The stromal loss of miR-4516 promotes the FOSL1-dependent proliferation and malignancy of triple negative breast cancer.
Kim JE; Kim BG; Jang Y; Kang S; Lee JH; Cho NH
Cancer Lett; 2020 Jan; 469():256-265. PubMed ID: 31672492
[TBL] [Abstract][Full Text] [Related]
24. Proliferation-associated long noncoding RNA, TMPO-AS1, is a potential therapeutic target for triple-negative breast cancer.
Mitobe Y; Ikeda K; Sato W; Kodama Y; Naito M; Gotoh N; Miyata K; Kataoka K; Sasaki H; Horie-Inoue K; Inoue S
Cancer Sci; 2020 Jul; 111(7):2440-2450. PubMed ID: 32437068
[TBL] [Abstract][Full Text] [Related]
25. Engineering macrophage-derived exosomes for targeted chemotherapy of triple-negative breast cancer.
Li S; Wu Y; Ding F; Yang J; Li J; Gao X; Zhang C; Feng J
Nanoscale; 2020 May; 12(19):10854-10862. PubMed ID: 32396590
[TBL] [Abstract][Full Text] [Related]
26. Filamin A (FLNA) modulates chemosensitivity to docetaxel in triple-negative breast cancer through the MAPK/ERK pathway.
Zhao P; Ma W; Hu Z; Zang L; Tian Z; Zhang K
Tumour Biol; 2016 Apr; 37(4):5107-15. PubMed ID: 26546439
[TBL] [Abstract][Full Text] [Related]
27. GSK3β regulates epithelial-mesenchymal transition and cancer stem cell properties in triple-negative breast cancer.
Vijay GV; Zhao N; Den Hollander P; Toneff MJ; Joseph R; Pietila M; Taube JH; Sarkar TR; Ramirez-Pena E; Werden SJ; Shariati M; Gao R; Sobieski M; Stephan CC; Sphyris N; Miura N; Davies P; Chang JT; Soundararajan R; Rosen JM; Mani SA
Breast Cancer Res; 2019 Mar; 21(1):37. PubMed ID: 30845991
[TBL] [Abstract][Full Text] [Related]
28. Role of SMC1 in overcoming drug resistance in triple negative breast cancer.
Yadav S; Sehrawat A; Eroglu Z; Somlo G; Hickey R; Yadav S; Liu X; Awasthi YC; Awasthi S
PLoS One; 2013; 8(5):e64338. PubMed ID: 23717600
[TBL] [Abstract][Full Text] [Related]
29. Targeted imaging and inhibition of triple-negative breast cancer metastases by a PDGFRβ aptamer.
Camorani S; Hill BS; Collina F; Gargiulo S; Napolitano M; Cantile M; Di Bonito M; Botti G; Fedele M; Zannetti A; Cerchia L
Theranostics; 2018; 8(18):5178-5199. PubMed ID: 30429893
[TBL] [Abstract][Full Text] [Related]
30. MEK-dependent IL-8 induction regulates the invasiveness of triple-negative breast cancer cells.
Kim S; Lee J; Jeon M; Lee JE; Nam SJ
Tumour Biol; 2016 Apr; 37(4):4991-9. PubMed ID: 26537583
[TBL] [Abstract][Full Text] [Related]
31. Cardamonin, a chalcone, inhibits human triple negative breast cancer cell invasiveness by downregulation of Wnt/β-catenin signaling cascades and reversal of epithelial-mesenchymal transition.
Shrivastava S; Jeengar MK; Thummuri D; Koval A; Katanaev VL; Marepally S; Naidu VGM
Biofactors; 2017 Mar; 43(2):152-169. PubMed ID: 27580587
[TBL] [Abstract][Full Text] [Related]
32. Propolin G-Suppressed Epithelial-to-Mesenchymal Transition in Triple-Negative Breast Cancer Cells via Glycogen Synthase Kinase 3β-Mediated Snail and HDAC6-Regulated Vimentin Degradation.
Pai JT; Chen XH; Leu YL; Weng MS
Int J Mol Sci; 2022 Jan; 23(3):. PubMed ID: 35163593
[TBL] [Abstract][Full Text] [Related]
33. Anti-progranulin/GP88 antibody AG01 inhibits triple negative breast cancer cell proliferation and migration.
Guha R; Yue B; Dong J; Banerjee A; Serrero G
Breast Cancer Res Treat; 2021 Apr; 186(3):637-653. PubMed ID: 33616772
[TBL] [Abstract][Full Text] [Related]
34. Multiple suppressing small interfering RNA for cancer treatment-Application to triple-negative breast cancer.
Lee J; Bang JH; Ryu YC; Hwang BH
Biotechnol J; 2023 Nov; 18(11):e2300060. PubMed ID: 37478121
[TBL] [Abstract][Full Text] [Related]
35. Rad51 Silencing with siRNA Delivered by Porous Silicon-Based Microparticle Enhances the Anti-Cancer Effect of Doxorubicin in Triple-Negative Breast Cancer.
Wu Z; Zhu L; Mai J; Shen H; Xu R
J Biomed Nanotechnol; 2021 Dec; 17(12):2351-2363. PubMed ID: 34974858
[TBL] [Abstract][Full Text] [Related]
36. Flubendazole elicits anti-cancer effects via targeting EVA1A-modulated autophagy and apoptosis in Triple-negative Breast Cancer.
Zhen Y; Zhao R; Wang M; Jiang X; Gao F; Fu L; Zhang L; Zhou XL
Theranostics; 2020; 10(18):8080-8097. PubMed ID: 32724459
[No Abstract] [Full Text] [Related]
37. Identification of the Novel Tumor Suppressor Role of FOCAD/miR-491-5p to Inhibit Cancer Stemness, Drug Resistance and Metastasis via Regulating RABIF/MMP Signaling in Triple Negative Breast Cancer.
Huang WC; Chi HC; Tung SL; Chen PM; Shih YC; Huang YC; Chu PY
Cells; 2021 Sep; 10(10):. PubMed ID: 34685504
[TBL] [Abstract][Full Text] [Related]
38. FOXM1 regulates expression of eukaryotic elongation factor 2 kinase and promotes proliferation, invasion and tumorgenesis of human triple negative breast cancer cells.
Hamurcu Z; Ashour A; Kahraman N; Ozpolat B
Oncotarget; 2016 Mar; 7(13):16619-35. PubMed ID: 26918606
[TBL] [Abstract][Full Text] [Related]
39. MCP-1 is overexpressed in triple-negative breast cancers and drives cancer invasiveness and metastasis.
Dutta P; Sarkissyan M; Paico K; Wu Y; Vadgama JV
Breast Cancer Res Treat; 2018 Aug; 170(3):477-486. PubMed ID: 29594759
[TBL] [Abstract][Full Text] [Related]
40. PRKCQ promotes oncogenic growth and anoikis resistance of a subset of triple-negative breast cancer cells.
Byerly J; Halstead-Nussloch G; Ito K; Katsyv I; Irie HY
Breast Cancer Res; 2016 Sep; 18(1):95. PubMed ID: 27663795
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]